Learn about FDA-cleared CELLSEARCH® Circulating Tumor Cell (CTC) Test for determining the prognosis of patients with metastatic breast, prostate, or colorectal cancer
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
PROVENGE, an autologous cellular immunotherapy used as a treatment for asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (CRPC). Visit www.provengehcp.com
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Learn about FDA-cleared CELLSEARCH® Circulating Tumor Cell (CTC) Test for determining the prognosis of patients with metastatic breast, prostate, or colorectal cancer
Learn about FDA-cleared CELLSEARCH® Circulating Tumor Cell (CTC) Test for determining the prognosis of patients with metastatic breast, prostate, or colorectal cancer
PROVENGE, an autologous cellular immunotherapy used as a treatment for asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (CRPC). Visit www.provengehcp.com
Learn about FDA-cleared CELLSEARCH® Circulating Tumor Cell (CTC) Test for determining the prognosis of patients with metastatic breast, prostate, or colorectal cancer
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Jevtana® (cabazitaxel) Injection is indicated for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Sipuleucel-T Impact Trial Video. First in class autologous immunotherapy developed to treat patients with metastatic castrare resistant prostate cancer. Lower Baseline prostate-specific antigen is associated with a greater overall survival benefit from S